To evaluate the role of disseminated intravascular coagulation (DIC) and to determine the influence of antithrombin, protein C, and plasminogen activator inhibitor 1 on multiple organ dysfunction syndrome (MODS) and outcome in patients with systemic inflammatory response syndrome (SIRS), we made a prospective cohort study. The study subjects consisted of thirty-five patients who exhibited two or more of the conditions of SIRS for more than three consecutive days. They were classified into subgroups of survivors (n = 13) and nonsurvivors (n = 22). The global coagulation and fibrinolytic markers, antithrombin, protein C, and plasminogen activator inhibitor 1 were measured on the day of the diagnosis of SIRS, and also on the 1st, 3rd, and 5th days. The results of these measurements, demographic data, criteria of severity, incidence of MODS were compared between the subgroups. For prediction of patient’s death, a receiver operating characteristic (ROC) curve analysis was made. DIC was frequently associated with SIRS patients (29/35, 82.9%). A significant decrease in the DIC score was found in the survivors (p = 0.0001). None of them suffered from DIC on the 5th day. In the nonsurvivors, low levels of protein C and antithrombin and markedly high values of plasminogen activator inhibitor 1 continued up to the 5th day, no improvement of the DIC was observed during the study period and the number of the dysfunctioning organs were significantly higher than in the survivors. Plasminogen activator inhibitor 1 on the 5th day had prognostic value for the prediction of death on the SIRS patients. In conclusion, DIC occurs commonly in patients with SIRS and may be the main determinant for the outcome of these patients. Changes in antithrombin, protein C, and plasminogen activator inhibitor 1 are one of the aggravating factors of MODS. Furthermore, plasminogen activator inhibitor 1 is a good predictor of death in these patients.
References
1
Marder VJ,
Feinstein DI,
Francis CW,
Colman RW.
Consumptive thrombo-hemorrhagic disorders. In: Hemostasis and Thrombosis. Basic principles and clinical practice, 3rd ed
Colman RW,
Hirsch J,
Marder VJ,
Salzman EW.
eds
Philadelphia: Lippincott; 1994: 1023-1063
2
Levi M,
ten Cate H,
van der Poll T,
van Deventer SGH.
Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
4
Fourrier F,
Chopin C,
Goudemand J,
Hendrycx S,
Caron C,
Rime A,
Marey A,
Lestavel P.
Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823
7 American College of Chest Physicians/Society of Critical Care Medicine consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 20. 864-874
8 Scientific and Standardization Committee Communications.]. Nomenclature of quantities and units in thrombosis and haemostasis (Recommendation 1993). Thromb Haemost 1994 71. 375-394
14
Hanley JA,
McNeil BJ.
A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843
16
Francis RB,
Seyfert U.
Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: Clinicopathologic correlations. J Lab Clin Med 1987; 110: 541-547
17
Hesselvik JF,
Blomback M,
Brodin B,
Mailer R.
Coagulation, fibrinolysis, and kallikrein system in sepsis: Relation to outcome. Crit Care Med 1989; 17: 724-733
19
Kruithof EKO,
Guidinchet A,
Bachmann F.
Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988; 59: 7-12
21
Hellgren M,
Egberg N,
Eklund J.
Blood coagulation and fibrinolytic factors and their inhibitors in criticially ill patients. Intensive Care Med 1984; 10: 23-28
